HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Statin Labeling Changes Include Class Warning About Glucose Effects

This article was originally published in The Pink Sheet Daily

Executive Summary

All statin labels now warn that “increases in HbA1C and fasting serum glucose levels have been reported” with the cholesterol-lowering drugs. Labels also reflect a relaxation of hepatic monitoring requirements, which could remove one hurdle to Pfizer’s pursuit of an OTC switch for Lipitor.

You may also be interested in...

FDA Considers “New Paradigm” To Facilitate Third Class Of Drugs

Approach that “under conditions of safe use” would allow nonprescription access to some categories of Rx drugs for treating chronic conditions is among topics for FDA hearing on switching Rx products to behind-the-counter status or other alternative routes.

Pfizer Will Delay Lipitor Switch Until Rx Revenues Fade

FDA Looks To Standardize New Hepatic Warnings For Statins

FDA appears to be taking steps to standardize new safety labeling across the statin class of cholesterol-lowering drugs.

Related Content


Related Companies

Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts